Leading chronic plaque psoriasis companies in the market include Zai Lab, UCB Biopharma SRL, Taizhou Mabtech Pharmaceutical, Sun Pharma, Janssen Research & Development, Livzon Pharmaceuticals, Alza Corporation, Delaware, USA, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma SRL, ApoPharma, Cellceutix Corporation, Kadmon Corporation, LLC, Novartis, Coherus Biosciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL and others.

DelveInsight's "Chronic Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast - 2034" report provides comprehensive insights into chronic plaque psoriasis, including historical and forecast epidemiology along with market trends in the US, EU4 (Germany, Spain, Italy, France), UK, and Japan.

To understand in more detail the chronic plaque psoriasis market outlook, medication uptake, treatment status and epidemiological trends, click here.Chronic Plaque Psoriasis Market Forecast

Some of the key facts of the Chronic Plaque Psoriasis Market report:

  • The chronic plaque psoriasis market is projected to witness significant growth at a significant CAGR throughout the study period (2020-2034)
  • In February 2025, Vyne Therapeutics initiated a randomized Phase Ib clinical trial with the first participants receiving VYN202, an oral treatment for moderate to severe plaque psoriasis. The double-blind, placebo-controlled study features three dose groups to evaluate safety, pharmacokinetics, and tolerability. Participants will receive 0.25 mg, 0.5 mg, or 1 mg of VYN202, or a placebo, once daily for 12 weeks.
  • In December 2024, Bristol-Myers Squibb Company (NYSE: BMY) announced results from the POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055) Phase 3 trials evaluating the efficacy and safety of Sotyktu (duclavacitinib) in adults with active psoriatic arthritis (PsA). Both studies met their primary endpoints, with significantly more patients treated with Sotyktu achieving an ACR20 response and at least a 20% improvement in disease symptoms after 16 weeks compared to placebo.
  • The chronic plaque psoriasis market in the United States was valued at approximately USD 14 billion in 2023. It is expected to grow at a CAGR of 2.8% during the forecast period (2024-2034).
  • Within the 7MM, the prevalence of chronic plaque psoriasis will be highest in the United States, with approximately 6.4 million reported in 2023. These figures are expected to increase throughout the forecast period.
  • In 2023, approximately 80% of chronic plaque psoriasis cases were classified as mild.
  • In the United States, there will be approximately 6,425,000 diagnosed cases of plaque psoriasis in 2023. These cases are expected to increase during the forecast period 2024-2034.
  • According to the National Psoriasis Foundation, psoriasis affects approximately 125 million people worldwide, including about 14 million in Europe and more than 8 million in the U.S. Of these patients, approximately 80-90% suffer from plaque psoriasis.
  • In September 2023, Takeda announced encouraging top-line results from a Phase IIb trial, a randomized, double-blind, placebo-controlled study evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with enhanced selectivity for individuals with active psoriatic arthritis.
  • The National Psoriasis Foundation reports that plaque psoriasis, the most common form of psoriasis, appears as raised, reddish patches covered with a buildup of whitish dead skin cells. About 20 percent of people with psoriasis have moderate to severe plaque psoriasis.
  • According to the Centers for Disease Control and Prevention (2020), psoriasis is the leading inflammatory disease in the United States, affecting approximately 7.4 million American adults.
  • Chronic plaque psoriasis is the most common type of psoriasis, affecting approximately 90% of people with the condition. Of those affected, approximately 20% to 30% experience moderate to severe symptoms.

Major players in Chronic Plaque Psoriasis:

Zai Lab, UCB Biopharma SRL, Taizhou Mabtech Pharmaceutical, Sun Pharma, Janssen Research & Development, Livzon Pharmaceutical, Alza Corporation, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma SRL, Arcutis Biotherapeutics, Pfizer, Arcutis Biotherapeutics, Inc., Coherus Biosciences, Inc., Samsung Bioepis Co., Ltd., Alvotech Swiss AG ApoPharma Cellceutix Corporation Kadmon Corporation, LLC Novartis Coherus Biosciences AbbVie Galderma R&D UCB Biopharma SRLไป–

The main treatments for chronic plaque psoriasis are:

ZL-1102, certolizumab pegol, CMAB015, tildrakizumab, guselkumab, LZM012, RWJ-445380, M923, LAS41008, bimekizumab, topical roflumilast, PF-06700841, ARQ-151, CHS cream 140%. Humira (adalimumab), adalimumab, MT-1303, Apo805K1, prulisol, belmosudil, secukinumab, etanercept, adalimumab, alefacept, calcitriol 3mcg/g, certolizumab pegol, etc.

  • Epidemiological analyses of chronic plaque psoriasis have shown that men are more susceptible to chronic plaque psoriasis than women.
  • The chronic plaque psoriasis market is expected to expand due to the increasing prevalence and awareness of the disease during the forecast period. Moreover, the launch of various multi-stage chronic plaque psoriasis pipeline products will dramatically change the dynamics of the chronic plaque psoriasis market.

Get a free sample of Chronic Plaque Psoriasis Market Forecast, Size, Share Analysis Report:

https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market

Overview of Chronic Plaque Psoriasis

Chronic plaque psoriasis is the most common form of psoriasis and is a chronic autoimmune skin disease characterized by red, raised, scaly patches known as plaques. These plaques usually appear on the scalp, knees, elbows, lower back, and other areas of the body. Chronic plaque psoriasis tends to persist for long periods of time, with periods of exacerbation and remission.

Epidemiology of chronic plaque psoriasis

The epidemiology section provides insights into the past, current, and projected epidemiological trends in the 7MM countries from 2020 to 2034. It helps in recognizing the causes of current and projected trends by exploring numerous studies and the views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient populations and future trends.

Epidemiological segmentation of chronic plaque psoriasis:

The Chronic Plaque Psoriasis Market report provides an epidemiological analysis for the study period 2020-2034 in the 7MM, segmented as follows:

  • Total prevalence of chronic plaque psoriasis
  • Prevalent cases of chronic plaque psoriasis by severity
  • Gender-specific prevalence of chronic plaque psoriasis
  • Cases diagnosed with episodic and chronic plaque psoriasis

Download the report to understand what factors are driving epidemiological trends in chronic plaque psoriasis @Epidemiological prediction of chronic plaque psoriasis

Chronic Plaque Psoriasis Drug Uptake and Pipeline Development Activity

The drug uptake section focuses on the uptake rate of potential drugs that have been recently launched in the chronic plaque psoriasis market or are scheduled to be launched during the study period. The analysis covers chronic plaque psoriasis market uptake by drugs, patient uptake by treatment modality, and sales of each drug.

Additionally, the therapeutic drug evaluation section helps you understand which drugs are most rapidly taken and why they are used to the fullest extent. Additionally, it compares medicines based on their market share.

The report also covers the pipeline development activities for chronic plaque psoriasis. It offers valuable insights into various therapeutic candidates at different stages and the key companies involved in the development of targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, details of licensed patents, and other information regarding novel treatments.

Chronic Plaque Psoriasis Treatments and Major Companies

  • ZL-1102: ZiLab
  • Certolizumab pegol: UCB Biopharma SRL
  • CMAB015: Taizhou Mabtech Pharmaceutical
  • Tildrakizumab: Sun Pharma
  • Guselkumab: Janssen Research and Development
  • LZM012: Livzon Pharmaceuticals
  • RWJ-445380: Alza Corporation, Delaware, USA
  • M923: Momenta Pharmaceuticals
  • LAS41008: Almirall, SA
  • Bimekizumab: UCB Biopharma SRL
  • Topical Roflumilast: Arcutis Biotherapeutics
  • PF-06700841: Pfizer
  • ARQ-151 0.3% cream: Arcutis Biotherapeutics, Inc.
  • CHS-1420: Coherus Biosciences, Inc.
  • Humira (adalimumab): Samsung Bioepis Co., Ltd.
  • Adalimumab: Alvotech Swiss AG
  • MT-1303: Mitsubishi Tanabe Pharma
  • Apo805K1: ApoPharma
  • Plulisol: Cellceutix Corporation
  • Belmosdir: Kadmon Corporation, LLC
  • Secukinumab: Novartis
  • Etanercept: Coherus Biosciences
  • Adalimumab: AbbVie
  • Alefaccept: Astellas Pharma
  • Calcitriol 3mcg/g: Galderma R&D
  • Certolizumab pegol: UCB Biopharma SRL

Find out more about the treatments expected to capture a major share in the chronic plaque psoriasis market @Treatment for chronic psoriasis vulgaris

Strengths of the chronic plaque psoriasis market

  • Increased investments in disease awareness campaigns, direct-to-consumer advertising, and various private/government initiatives will increase the likelihood of adoption and adherence to treatments, thereby driving market growth during the forecast period.
  • The increasingly prevalent cases of psoriasis can be seen as an expanding potential market, making it an attractive therapeutic area for investment.

Chronic Plaque Psoriasis Market Opportunity

  • Patients with chronic plaque psoriasis face significant challenges due to the lack of curative treatment options.
  • Anti-TNF drugs are considered one of the most effective drug classes, however, their use is associated with immunogenicity and significant side effects.

Scope of the Chronic Plaque Psoriasis Market Report

  • Research period: 2020-2034
  • Coverage: 7MM [US, EU5 (Germany, France, Italy, Spain, UK), and Japan]
  • Key players in chronic plaque psoriasis: Zai Lab, UCB Biopharma SRL, Taizhou Mabtech Pharmaceutical, Sun Pharma, Janssen Research & Development, Livzon Pharmaceutical, Alza Corporation, Delaware, USA, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma SRL, Arcutis Biotherapeutics, Pfizer, Arcutis Biotherapeutics, Inc., Coherus Biosciences, Inc., Samsung Bioepis Co., Ltd., Alvotech Swiss AG, Mitsubishi Tanabe Pharma, ApoPharma, Cellceutix Corporation, Kadmon Corporation, LLC, Novartis, Coherus Biosciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL and others.
  • Key chronic plaque psoriasis treatments: ZL-1102, certolizumab pegol, CMAB015, tildrakizumab, guselkumab, LZM012, RWJ-445380, M923, LAS41008, bimekizumab, topical roflumilast, PF-08150, ARQ-04151 0.3% cream, CHS-1420, Humira (adalimumab), adalimumab, MT-1303, Apo805K1, prurisol, belmosudil, secukinumab, etanercept, adalimumab, alefacept, calcitriol 3mcg/g, certolizumab pegol, etc.
  • Evaluation of chronic plaque psoriasis treatments: currently available treatments for chronic plaque psoriasis and new treatments for chronic plaque psoriasis
  • Chronic Plaque Psoriasis Market Dynamics: Chronic Plaque Psoriasis Market Drivers and Chronic Plaque Psoriasis Market Barriers
  • Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG matrix, market entry strategy
  • Unmet Needs in Chronic Plaque Psoriasis, KOL Perspectives, Analyst Perspectives, Market Access and Reimbursement in Chronic Plaque Psoriasis

For more information on companies operating in the chronic plaque psoriasis treatment market, please visit @Clinical trials and treatment evaluations for chronic plaque psoriasis

table of contents

  1. Introduction to the Chronic Plaque Psoriasis Market Report
  2. Chronic Plaque Psoriasis Overview
  3. SWOT Analysis of Chronic Plaque Psoriasis
  4. Overview of the percentage of people with chronic plaque psoriasis
  5. Overview of Chronic Plaque Psoriasis Market
  6. Background and overview of chronic plaque psoriasis
  7. Epidemiology and prevalence of chronic plaque psoriasis
  8. Number of chronic plaque psoriasis patients by country
  9. Current Treatments and Medical Procedures for Chronic Plaque Psoriasis
  10. Unmet Needs in Chronic Plaque Psoriasis
  11. A new treatment for chronic plaque psoriasis
  12. Chronic Plaque Psoriasis Market Outlook
  13. Chronic Plaque Psoriasis Market Analysis by Country (2020–2034)
  14. Market Access and Reimbursement for Treatment of Chronic Plaque Psoriasis
  15. Chronic Plaque Psoriasis Market Drivers
  16. Chronic Plaque Psoriasis Market Barriers
  17. Chronic plaque psoriasis appendix
  18. How to report chronic plaque psoriasis
  19. DelveInsight Features
  20. Disclaimer
  21. About DelveInsight

About DelveInsight

DelveInsight is a leading healthcare business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.

We also provide healthcare consulting services that help in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Information

Kanishk

Email-kkumar@delveinsight.com